-
1 Comment
Zhejiang Ausun Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 11.0% below its 200 day moving average.
From a valuation standpoint, the stock is 104.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 19.7.
Zhejiang Ausun Pharmaceutical Co., Ltd's total revenue rose by 24.0% to $92M since the same quarter in the previous year.
Its net income has dropped by 29.4% to $14M since the same quarter in the previous year.
Finally, its free cash flow fell by 35.3% to $9M since the same quarter in the previous year.
Based on the above factors, Zhejiang Ausun Pharmaceutical Co., Ltd gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | SHG |
| CurrencyCode | CNY |
| ISIN | CNE100002XK2 |
| PE Ratio | 24.81 |
|---|---|
| Beta | 0.13 |
| Market Cap | 7B |
| Target Price | 20.39 |
| Dividend Yield | None |
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it offers development and manufacturing services to the pharmaceutical, cosmetics, and nutritional industries. The company was founded in 2010 and is based in Linhai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603229.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
